From the success of Informa Life Sciences' first ADC conference, we are delighted to bring to you our 2nd Conference on Antibody-Drug Conjugates.

Antibody-drug conjugates are the new talking point of the biotech world. With multi-million pound partnership deals being sealed like never before, it is no wonder nearly all industry players are fighting, or preparing to fight, for their piece of the ADC market.

With only one ADC approved and on the market, from Seattle Genetics for the treatment of Hodgkin's Lymphoma, the importance of understanding how best to monitor the toxicity and pK, as well as improve targeting and payload delivery for improved potency is essential for the success of your drug.

To address these increasing concerns, we bring to you our 2012 conference dedicated entirely to the design (novel payload and delivery strategies), preclinical, clinical, regulatory, analytical and process development hurdles faced by these novel products. We have worked hard to cover this impressive scope of ADC specific issues with expert speakers from companies including Seattle Genetics, Genmab, Immunogen, Pfizer and more!

For the FIRST TIME, discover how best to monitor your drug in the clinic: Hear how to analyse the pK and immunogenicity as well as determining and assessing quality attributes for the ADC

With the inclusion of a dedicated poster session, networking dinner, evening seminar & pre- and post-conference workshop to enhance your learning and networking opportunities, this new event is set to be truly excellent and should not be missed!